Alimera Sciences, Inc. is a biopharmaceutical company. The Company researches, develops and commercializes the prescription of ophthalmic pharmaceuticals. The Company focuses on diseases affecting the back of the eye. The Company’s product is ILUVIEN, an implant providing a therapeutic effect for up to 36 months in the treatment of vision impairment associated with chronic diabetic macular edema (DME) by delivering sustained sub-microgram levels of Fluocinolone Acetonide (FAc), a non-proprietary corticosteroid. ILUVIEN consists of a tiny polyimide tube with a membrane cap. ILUVIEN is inserted in a non-surgical procedure employing a device with a 25-gauge needle, which allows for a self-sealing wound. ILUVIEN is approved for chronic DME in the United Kingdom and European Union. ILUVIEN is also studied in three Phase II clinical trials for the treatment of the dry form of age-related macular degeneration (AMD), the wet form of AMD and retinal vein occlusion (RVO).